Parent and group
- Sukhino100%
- Colruyt Group100%
- KORYS66.52%
APOTHEEK NOORDERLAAN
ActiveSummary
APOTHEEK NOORDERLAAN has been active since 2007 and the Belgian Official Gazette contains no insolvency or warning signals. The 2026 annual accounts show equity of €853,762 and a net result of -€132,472. Equity has been growing by about 2.8% per year since 2019. Its solvency ranks better than 77% of 372 sector peers (NACE 47, financial year 2026). The computed 12-month bankruptcy probability is 0.6% (low).
Overview
Official details
Source: KBO- Status
- Active since 18-12-2007 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 31-03-2024
- Establishment unit
- 2.169.695.307 2030 Antwerpen, since 01-01-2008
- Financial year end
- 31 March
- Peppol
- Reachable since 24-11-2023
Board and ownership
Board
- Colruyt JozefDirector · since 31-05-2023
- Jo WillemynsDirector · since 31-05-2023
- Kris CasteleinDirector · since 31-05-2023
Shareholders
- NEWPHARMA GROUP100%· score 8631-03-2026 annual accounts of NEWPHARMA GROUP
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.6%
Annual accounts to 31-03-2026
- Gross margin
- €272,744
- ▼ 32.9%
- Turnover
- ≈ €990,000
- estimated
- Loss
- €132,472
- Equity
- €853,762
- ▼ 13.4%
- Total assets
- €1.3m
- ▲ 9.9%
- Employees on 31-03-2026
- 4
- ▲ 33.3%
Score breakdownraises riskLoss of €132,472 (financial year 2026)Liquidity: current ratio 0.96, cash €12,518lowers riskEquity €853,762 (64.8% of total assets)Figures for financial year 2026 (filed on 23-09-2026)Show the evidence
Checked score
Score 2026
80
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 38% of micro companies in retail trade (NACE 47)
Financial strength · tick: 2025
Weak
Solvency
90-10
equity 64.8% of total assets
Liquidity
35-11
short-term debt 35.2% · cash 1.0%
Profitability
10-43
return on assets -10.1%
Bankruptcy probability within 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025lowest value
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.1%● unchanged vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.2%▲ +0.1 percentage points vs 06-2026
08-2026: 0.2%● unchanged vs 07-2026
09-2026: 0.2%● unchanged vs 08-2026
10-2026: 0.6%▲ +0.4 percentage points vs 09-2026highest value
11-2026: 0.6%● unchanged vs 10-2026highest value
Credit of up to €65,000 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.96 (2.53 in 2025), below 1. Short-term debt is 35.2% and cash 1% of total assets. 35.2% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 77% of them on solvency, 33% on liquidity, 17% on profitability and 24% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2026 was due by 31-10-2026 and was filed on 21-09-2026, 40 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2026
40 days early
2025
37 days early
2024
1 day early
2022
62 days early
2021
59 days early
2020
61 days early
2019
43 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 43 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-03-2027 and is due by 31-10-2027. Nothing is late today. The company usually files around 24 September (3 of the last 3 accounts filed within 36 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
02-11-2026 today31-03-2027 year end31-10-2027 deadline
Key points
- Caution: From profit to loss in 2026after a profit of €55,370 in 2025 -€132,472 View
- Caution: Lower net result than 87% of companies in retail tradesector median €47,488 · 369 companies -€132,472 View
- Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
- New directorlatest change 01-08-2026 · 6 in office 1 joined View
Recent changes
- · Gazette deed Appointment: EY Bedrijfsrevisoren (statutory auditor)Permanent representative: Emilie VAN CALLEMONT
- · Gazette deed Appointment: EY Bedrijfsrevisoren (statutory auditor)Permanent representative: Emilie VAN CALLEMONT
- · Gazette deed Resignations: Ilse Krols Comm. V., LK2 BV and 5 othersPermanent representatives: Ilse Krols, Luc Kleynjans and 5 others · Appointments: Jef Colruyt, Stefaan Vandamme and 3 others
Companies linked to APOTHEEK NOORDERLAAN
Comparable companies
These companies have the same main activity as APOTHEEK NOORDERLAAN: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.2m and €1.4m, founded between 2001 and 2007.
| Company | Total assets | Gross margin |
|---|---|---|
| APOTHEEK NOORDERLAAN Antwerpen | €1.3m | €0.3m |
| APOTHEEK DE KROON Antwerpen | €1.4m | €0.3m |
| Apothekers MARIABURG Brasschaat Brasschaat | €1.3m | €0.3m |
| Pharmacie de Vesnau Ittre | €1.2m | €0.3m |
| MANAGEMENT AELBERS Dilsen-Stokkem | €1.3m | €0.3m |
| CONEMPHAR Mons | €1.4m | €0.3m |
| PHARMACIE H. DOCK Faimes | €1.3m | €0.3m |
Key facts about APOTHEEK NOORDERLAAN
- What is the company number of APOTHEEK NOORDERLAAN?
- The company number of APOTHEEK NOORDERLAAN is 0894.785.309. The VAT number is the same number with BE in front: BE 0894.785.309.
- Where is APOTHEEK NOORDERLAAN based?
- The registered office is at Noorderlaan 104, 2030 Antwerpen.Company details
- What does APOTHEEK NOORDERLAAN do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of APOTHEEK NOORDERLAAN?
- The legal form of APOTHEEK NOORDERLAAN is Public limited company (NV).
- When was APOTHEEK NOORDERLAAN founded?
- APOTHEEK NOORDERLAAN was founded on 18-12-2007.
- Is APOTHEEK NOORDERLAAN still active?
- Yes, APOTHEEK NOORDERLAAN is an active enterprise in the KBO register.
- How many employees does APOTHEEK NOORDERLAAN have?
- APOTHEEK NOORDERLAAN had an average of 3.5 full-time equivalents in financial year 2026, according to the filed annual accounts.Financials
- Which joint committee does APOTHEEK NOORDERLAAN fall under?
- In its 31-03-2024 annual accounts, APOTHEEK NOORDERLAAN states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of APOTHEEK NOORDERLAAN?
- The turnover in financial year 2026 is ≈ €990,000. This figure is estimated from the gross margin of €272,744 and 47 comparable companies (NACE 477). It probably lies between €770,000 and €1.6m.
- Is APOTHEEK NOORDERLAAN profitable?
- In financial year 2026, APOTHEEK NOORDERLAAN made a loss of €132,472.
- Where can I find the annual accounts of APOTHEEK NOORDERLAAN?
- APOTHEEK NOORDERLAAN filed 17 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
- When are the next annual accounts of APOTHEEK NOORDERLAAN due?
- APOTHEEK NOORDERLAAN must file the annual accounts for financial year 2027 by 31-10-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See the other companies in the same group.KORYS · 179 companies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.